ConductScience.org, home

Gene · 64761

PARP12: poly(ADP-ribose) polymerase family member 12

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. PARP12: poly(ADP-ribose) polymerase family member 12. Genes, record 64761. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/64761

On this page

Gene

Symbol
PARP12
HGNC
Name
poly(ADP-ribose) polymerase family member 12
HGNC
NCBI Gene ID
64761
NCBI Gene
HGNC ID
HGNC:21919
HGNC
Ensembl
ENSG00000059378
NCBI Gene
Aliases
ARTD12, FLJ22693, MST109, MSTP109, PARP-12, ZC3H1, ZC3HDC1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q9H0J9Protein mono-ADP-ribosyltransferase PARP127013Ensembl, GeneID, HGNC

Source UniProt

Patents35

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1458315Q9H0J9Espacenet
EP 4641201 A22025-10-291794Q9H0J9Espacenet
JP 2025147176 A2025-10-0615455Q9H0J9Espacenet
JP 2025517969 A2025-06-121794Q9H0J9Espacenet
JP 2025028160 A2025-02-2815455Q9H0J9Espacenet
KR 1020250010750 A2025-01-2115455Q9H0J9Espacenet
JP 2024109657 A2024-08-1415294Q9H0J9Espacenet
US 11884978 B22024-01-30645Q9H0J9Espacenet
US 11446398 B22022-09-2064523Q9H0J9Espacenet
JP 2022524081 A2022-04-27167494Q9H0J9Espacenet

1 to 10 of 35

See all 35 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,050

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePARP12 papersNewest fiscal year
P30CA016672Cancer Center Support Grant242025
P20GM113117Chemical Biology of Infectious Disease112025
R01DK069710The Role of Nuclear PARPs in Signal-Regulated Transcription92025
P30CA008748Cancer Center Support Grant82025
P30CA014051Cancer Center Support (Core) Grant82025
P30CA047904Cancer Center Support Grant72025
P01CA092584Structural Cell Biology of DNA Repair Machines62025
R35GM138029Determining mechanisms of innate immune modulation by ADP-ribosylation62025
ZIABC006150DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs62025
ZIABC011078Phase 0-1 Clinical Trials62025

1 to 10 of 1,050Source NIH's project files

See all 1,050 nih grants

Papers1,639

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
XYL-1 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Suppressing the SCD1/BRCA1 Signaling Pathway.Molecules202642653863PubTator, text miningPubMed
Beyond Catalytic Inhibition: The Evolving Landscape of PARP Pharmacology.Annu Rev Pharmacol Toxicol202642574757PubTator, text miningPubMed
From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.Front Oncol202642568603PubTator, text miningPubMed
Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy.ACS Chem Biol202642504699PubTator, text miningPubMed
PARP1 as a Central Node in DNA Repair and Epigenetic Regulation: Implications for Biomarker Discovery and Targeted Therapy in NSCLC.Mini Rev Med Chem202642474024PubTator, text miningPubMed
FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability.Nat Commun202642380136PubTator, text miningPubMed
Selective biological activity of parthenolide derivatives - stizolin, stizolicin, and izospiciformin - isolated from the leaves of Stizolophus balsamita, in different breast cancer molecular subtypes in vitro.
Front Pharmacol202642199856PubTator, text miningPubMed
PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer.Front Immunol202642148103PubTator, text miningPubMed
Unraveling the pyroptosis pathway: Key insights into methotrexate-induced liver injury.Biochem Pharmacol202642140447PubTator, text miningPubMed
A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients.Cancers (Basel)202642122217PubTator, text miningPubMed

1 to 10 of 1,639

See all 1,639 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/64761

GET https://conductscience.org/api/genes/v1/64761/patents?page=2